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Abstract
Rationale: Alpha particle emitting radiopharmaceuticals are generating considerable interest for the
treatment of disseminated metastatic disease. Molecular imaging of the distribution of these agents is
critical to safely and effectively maximize the clinical potential of this emerging drug class. The present
studies aim to investigate the feasibility and limitations of quantitative SPECT for 223Ra, 225Ac and 227Th.
Methods: Three state-of-the-art SPECT/CT systems were investigated: the GE Discovery NM/CT 670,
the GE Optima NM/CT 640, and the Siemens Symbia T6. A series of phantoms, including the NEMA IEC
Body phantom, were used to compare and calibrate each camera. Additionally, anthropomorphic physical
tumor and vertebrae phantoms were developed and imaged to evaluate the quantitative imaging
protocol.
Results: This work describes and validates a methodology to calibrate each clinical system. The efficiency
of each gamma camera was analyzed and compared. Using the calibration factors obtained with the
NEMA phantom, we were able to quantify the activity in 3D-printed tissue phantoms with an error of
2.1%, 3.5% and 11.8% for 223Ra, 225Ac, and 227Th, respectively.
Conclusion: The present study validates that quantitative SPECT/CT imaging of 223Ra, 225Ac, and 227Th is
achievable but that careful considerations for camera configuration are required. These results will aid in
future implementation of SPECT-based patient studies and will help to identify the limiting factors for
accurate image-based quantification with alpha particle emitting radionuclides.
Key words: radiopharmaceutical therapies; quantitative SPECT/CT; Radium-223; Actinium-225; Thorium-227

Introduction
The application of radiation to treat primary and
oligometastatic disease is a pillar of cancer therapy,
demonstrating efficacy in a wide range of cancer
types. However, in the metastatic setting, imageguided application of conventional external beam
irradiation is generally limited to palliative use. This
is because the inherent challenges in safely and
effectively applying sufficient dose to multiple sites

throughout the body, including occult micrometastases, make this approach infeasible. Systemic
administration of radiopharmaceutical therapies
(RPT) have the potential to deliver ablative doses to
myriad lesions, and this modality has a long history of
established clinical practice [1]. Here, pretherapeutic
imaging and pharmacokinetic information of RPT
distribution are important to measure absorbed doses
http://www.thno.org
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at both sites of disease and to avoid off-target normal
organ toxicities.
There has been a growing interest in application
of alpha particle (⍺)-emitting RPT for metastatic
disease. Alpha particles are charged helium nuclei
that deposit 5-10 MeV of energy in the range of only
50-100 of microns, resulting in potent cytotoxicity.
This produces complex DNA damage to both cancer
cells and normal tissues relative to conventional
radiotherapies. The biological impact and physical
characteristics of these emissions make the
quantitative imaging of the activity distribution
essential in order to optimize administered activities,
modify treatment plans, monitor accumulation, and
mitigate toxicity. There are several ⍺-emitting
radioisotopes with relevant biomedical properties
including 212Pb (parent of ⍺-emitting 212Bi; t1/2 = 10.6 h)
and 211At (t1/2 = 7.2 h). Among the most translationally
relevant, and the focus of this work, are the
longer-lived 223Ra (t1/2 = 11.4 days), which is approved
for use in treatment of metastatic castrate-resistant
prostate cancer (mCRPC), its parent, 227Th (t1/2 = 18.7
days), and 225Ac (t1/2 = 10 days).
Despite the long-standing interest, there are few
reports of quantitative imaging methods for
assessment of ⍺-RPT. Indeed, the combination of a
complex photon emission spectrum and the very low
activities administered to patients makes imaging of
⍺-emitting radiopharmaceuticals challenging because
of the low number of detectable photons. There is also
a need to compensate for the scatter and septal
penetration that constitutes a substantial part of the
acquired signal.
The efficacy of 223Ra in mCRPC patients has been
demonstrated in multiple studies [2-11] and this
radionuclide has three principal gamma emissions at
81, 154, and 270 keV [12]. Multiple reports have
shown that it is possible to acquire coarse imaging of
223Ra using planar methods [13-16], primarily using an
energy window centered on the 81 keV gamma
emission. Such gamma camera planar imaging can be
used to assess biodistribution and to calculate normal
organ dosimetry in patients treated with
223Ra-dichloride [14, 17-22], according to the Medical
Internal Radiation Dose (MIRD) formalism. Recently,
several studies have shown the feasibility of
quantitative single-photon emission computed
tomography (SPECT) [23-25] using physical-phantom
measurements. For example, Gustafson et al. [24]
showed that quantification of a 26.4 mL sphere in a
NEMA IEC Body phantom was achievable with errors
ranging from -25% to -34% with a GE Infinia
Hawkeye SPECT/CT gamma-camera (GE, Fairfield,
CT, USA) equipped with a medium-energy
collimator.
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225Ac

is currently used for antibody- and
peptide-labeled therapies under pre- and clinical
evaluation. In particular, there has been great interest
in 225Ac-PSMA-617 in several investigational studies
for patients with prostate cancer [26-28]. For patients
with advanced disease, treatment activities of 100
kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8
weeks have been administered [26, 27]. 225Ac has two
principal gamma emissions at 218 keV and 440 keV
[12] from its daughters 221Fr and 213Bi respectively,
along with bremsstrahlung X-rays from 209Pb.
Kratochwil et al. [28] have reported planar imaging of
patients treated with 225Ac-PSMA-617 using energy
windows centered around the two gamma emission
lines previously noted. In addition, Usmani et al.
recently demonstrated that addition of a 78 keV
photopeak provided improved quality of images with
a clearer distinction of lesions [29]. To the best of our
knowledge, a single report of quantitative 225Ac
imaging (for PSMA-targeted therapy) has been
evaluated [30]. However, the 213Bi daughter has been
investigated for tomographic imaging with
213Bi-DOTATOC. These have shown promising initial
results [31].
Finally, 227Th is also the subject of several
early-phase clinical trials using antibody targeted
vehicles, such as an alternative PSMA construct in
mCRPC patients (NCT03724747) [32, 33]. 227Th has
one principal gamma emission at 236 keV [12], and is
the parent of 223Ra; thus, its gamma emissions can also
be used for imaging. According to the work of Murray
et al. [34], planar imaging of 227Th is achievable using
multiple energy windows, and this approach may
provide quantitative value. Quantification of a 3 cm
diameter sphere in a water-filled cylinder phantom
227Th filled phantom by SPECT provided values
within an error of -12.4 ± 4.9%, using a Symbia Intevo
(Siemens) gamma camera equipped with a medium
energy-low penetration collimator [35].
These initial efforts for planar and tomographic
imaging of 223Ra, 225Ac, and 227Th are encouraging.
They motivate further characterization of the
properties of SPECT-based activity quantification for
⍺-RPT to allow for its use in patient studies to acquire
reliable information about their accumulation in both
sites of disease and at-risk organs. In general, SPECT
is considered superior to planar imaging for activity
quantification [36] with the primary advantage of
eliminating organ activity overlap and enabling more
accurate attenuation and scatter correction.
The present studies investigate the feasibility
and limitations of quantitative SPECT for 223Ra, 225Ac,
and 227Th. A series of phantom measurements were
performed on three state-of-the-art SPECT/CT
systems: GE Discovery NM/CT 670, GE Optima
http://www.thno.org
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NM/CT 640 and Siemens Symbia T6. This work
describes and validates a methodology to calibrate
each camera. The efficiency of each gamma camera is
analyzed and compared, with a primary focus on the
estimation of radioactivity concentration in lesions.
The long-term goal is to characterize these properties
to allow for future SPECT/CT-based patients studies
and to identify the limiting factors for accurate
image-based quantification with these potent
radiopharmaceuticals.

Methods
Radioisotopes
In this work, three ⍺-emitters have been studied:
225Ac, and 227Th. Figure S1 illustrates each
radionuclide’s decay scheme and Table 1 summarizes
the principal photon emissions. For imaging
evaluation, five phantoms were used: the
standardized NEMA IEC Body phantom, two custom
detection-limit phantoms, a tumor phantom, and a
vertebrae phantom. 225Ac and 227Th were supplied as
dry nitrates from the Department of Energy (Oak
Ridge National Laboratory) from 228Th and
227Ac-generator systems, respectively. 227Th samples
for spectroscopic and tomographic evaluation were
chemically purified at maximum of one day prior to
their use. Different sources of 223Ra solutions were
used for these studies. Xofigo (223RaCl2) was used for
energy spectrum and sensitivity measurements. For
the NEMA phantom and the high activity limit of
detection phantom, 223Ra was generated in our
laboratory from trace 227Ac, as previously reported
[37]. For the low activity limit of detection phantom
and the vertebrae phantom, 223Ra was produced in
our laboratory from 227Th. All samples used for
measurement were quality controlled by high
resolution gamma spectroscopy in order to verify
their identical radiological properties (for 223Ra
sources), and purity. A 1.5 mL conical polypropylene
vial was filled with 37 kBq of each radioisotope were
measured for 10 min on a high purity germanium
(HPGe) system (GEM-50195-S; Ortec). Samples were
placed directly on a high purity aluminum endcap
and the system was enclosed in a 10 cm lead shield
(HPLBS1, Ametek). Spectral acquisitions were
acquired and analyzed by Gamma-Vision Software
(version 8.0, Ametek).
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Technology traceable source was used to empirically
determine the dose calibrator value for 223Ra, as
previously described [36]. A National Physics
Laboratory (UK) traceable source, in preparation for
investigation clinical treatment studies with antibody
conjugates, was used to determine the dose calibrator
value for 227Th, and verified by HPGe measurements.
Table 1. Decay data for 223Ra, 225Ac and 227Th and their
daughters. The bolded energies are within the ideal energy range
of the gamma camera
Isotope Half-life Daughters
(days)
223Ra
11.43

223Ra,

Activity measurements
All sample activities were carefully measured
with the same ionization chamber radionuclide dose
calibrator (CRC-15; Capintec). The dial settings used
for 223Ra, 225Ac, and 227Th are 236, 72, and 91,
respectively. A National Institutes of Standards and

219

Rn
211

225

Ac

Th

211

Bi

213

Bi

211

Pb

10
221

227

Pb

Fr

18.68
223

Ra

219

Rn
211

Bi

Principal emitted photon energies
(keV) (% abundance)
11.7 (25.0), 81.1 (15.0), 83.8 (24.9),
94.9 (11.3), 144.2 (3.2), 154.2 (5.6),
269.5 (13.7) and 323.9 (3.9)
271.2 (10.8) and 401.8 (6.4)
404.9 (3.8) and 832.0 (3.5)
351.1 (12.9)
12.0 (6.9) and 14.8 (6.7)
218.2 (11.6)
440.5 (26.1)
12.3 (21.0), 50.1 (8.0), 236.0 (12.3)
and 256.3 (7.0)
11.7 (25.0), 81.1 (15.0), 83.8 (24.9),
94.9 (11.3), 144.2 (3.2), 154.2 (5.6),
269.5 (13.7) and 323.9 (3.9)
271.2 (10.8) and 401.8 (6.4)
404.9 (3.8) and 832.0 (3.5)
351.1 (12.9)

SPECT/CT camera characteristics
To evaluate vendor, collimator, and devicespecific effects on low activity ⍺-emitter SPECT
acquisition, we evaluated three dual-head SPECT/CT
cameras: a Discovery 670 and an Optima 640 SPECT/
CT from GE and a Symbia T6 from Siemens. All the
cameras were equipped with their specific set of
collimators: MEGP (medium energy general purpose)
for GE or MELP (medium energy low-penetration) for
Siemens and HEGP (high-energy general purpose) for
both vendors. Enclosed in Table 2 and Table 3 are the
camera system and collimator characteristics of each
unit, respectively.

Energy spectrum and sensitivity comparison
To set the energy windows for quantitative
imaging, the energy spectrum of each radioisotope
was measured on the Discovery 670 (GE) and Symbia
T6 (Siemens) with both collimators. Since the gamma
camera components from the Discovery 670 and the
Optima 640 are identical, the energy spectrum was
measured only on the Discovery 670. The source was
contained in a 5 mL glass vial and placed in the center
of the field of view between the two gamma camera
heads at a point 17 cm from both heads. The activity
in the source was 932 kBq, 2242 kBq, and 419 kBq for
223Ra, 225Ac, and 227Th, respectively.

http://www.thno.org
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Table 2. SPECT/CT systems specification and setup for ⍺-SPECT imaging

Table 3. Collimator Characteristics
SPECT/CT Camera Collimators Hole diameter Septal
GE 670 and 640
Siemens Symbia T6

MEGP
HEGP
MELP
HEGP

(mm)
3
4
2.94
3.4

Thickness (mm)
1.05
1.8
1.14
2

Hole Length
(mm)
58
66
40.64
50.8

The Symbia T6 offers the possibility of directly
measuring the energy spectrum without acquiring an
image. For the measurement on the Discovery 670, the
energy spectrum was assessed from planar images of
each source, acquired using energy windows covering
the range from 57 keV to 475 keV, totaling 59 energy
windows for 223Ra and 227Th and 43 energy windows
for 225Ac. Each acquisition was acquired for a duration
of 5 min. The emission energy windows were selected
to provide coverage of the relevant photopeaks
specific for each radioisotope, and a corresponding
scatter energy window was estimated on adjacent
lower energies.
In order to compare the performance of each
system, the sensitivity was measured for each
radioisotope and collimator. The same geometry and
sources, as described above, were used. Planar images
of each source, and an acquisition without any source
for background subtraction, were recorded using the
emission windows determined from the energy
spectrum for a duration of 10 min. The sensitivity,
denoted by S, was calculated as follows:
𝑆=

𝐶𝑜𝑢𝑛𝑡𝑠

𝐴×𝑇𝑎𝑐𝑞

(1);

where Counts denotes the total counts measured in a
region of interest (ROI) with the same area as the vial

and centered around it, after background subtraction;
Tacq is the acquisition duration (s), and A denotes the
nominal activity in the vial at the time of acquisition
(MBq).

Quantitative phantom study
A NEMA IEC Body phantom (Data Spectrum)
was used to investigate quantitative SPECT/CT
imaging characteristics. The NEMA phantom contains
6 spheres of different diameters: 3.7, 2.8, 2.2, 1.7, 1.3,
and 1.0 cm. Each sphere was filled with the same
activity concentration of the radioisotope: 40 kBq/mL
for 223Ra, 35 kBq/mL for 225Ac, and 40 kBq/mL for
227Th, with the main cavity of the phantom body filled
with non-radioactive water.
The phantom was placed in the center of the
field of view and SPECT/CT acquisitions were
performed with both MEGP/MELP and HEGP
collimators on each system with energy windows
determined from energy spectrum evaluation. The
body-contour acquisition orbit was utilized and 30 s
acquisitions per projection were acquired for every 6°,
over a 360° orbit.
The images acquired on the GE cameras were
reconstructed on the Xeleris software with the
following parameters: 2D-OSEM algorithm, 2
iterations, 10 subsets and Butterworth filter (fc = 0.48,
p = 10). The projections were corrected for scatter
using the corresponding scatter windows and the
dual-energy window (DEW) scatter-compensation
method [38] and attenuation using the CT-based
attenuation map. Indeed, during a SPECT/CT
acquisition, one image was generated for each
emission energy window and each scatter energy
http://www.thno.org
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window. The software also acquired CT-based
attenuation maps with attenuation coefficients
corresponding to each emission energy window.
Finally, the reconstructed images were summed to
evaluate combinations of energy windows.
The acquired data on the Symbia T6 were
reconstructed on the Esoft workstation (Siemens) with
the following parameters: 3D OSEM algorithm, 16
iterations, 4 subsets and Gauss filter (FWHM = 9 mm).
Attenuation correction was performed from the CT
using manufacturer’s default parameters. They were
not corrected for scatter, as this software does not
enable scatter correction for multiple energy window
acquisitions. Similar to the Xeleris software, the Esoft
workstation reconstructs each energy window
individually. Table 2 summarizes the acquisition and
reconstruction parameters used for the evaluation of
quantitative imaging of the phantom.
The reconstructed images were analyzed using
HERMES (v2.7.2, Hermes Medical Solutions).
Volumes of interest (VOIs) defined on the CT images
were applied to the SPECT data: 6 spheres of the same
dimensions of the spherical inserts of the NEMA
phantom. The total number of counts was obtained
for each sphere.
The calibration factor CF (counts/s/MBq) was
calculated for each sphere [39]:
𝐶

𝐶𝐹 = 𝐴×𝑇

𝑎𝑐𝑞

(2);

where C denotes the total reconstructed counts within
the target volume of interest, A is the activity present
in the sphere at the time of acquisition and Tacq
denotes the duration of the acquisition.
To compare imaging noise metrics, the central
slice traversing all six spheres was selected as the
target slice for analysis. A total of 36 background
spherical VOIs were defined for each sphere size (3.7,
2.8, 2.2, 1.7, 1.3, and 1.0 cm diameter) by positioning
12 background VOIs on the target slice, as well as on
two neighboring slices (slice positions ± 20 mm)
(Figure 1). The number of counts in each VOI was
reported using HERMES Hybrid Viewer and they
were used to calculate the signal to noise ratio (SNR)
and background variability (BV) [40]. The SNR was
defined as:
𝑆𝑁𝑅 =

𝐶ℎ𝑜𝑡 −𝐶𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑠𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

(3);

where Chot denotes the number of counts detected in a
hot sphere, Cbackground denotes the mean of number of
counts detected in the corresponding background
VOIs, and sbackground denotes the standard deviation of
the background VOIs.

Figure 1. Target slice of the SPECT/CT fusion of the NEMA phantom with activityfilled spheres. Location of VOIs for analysis are indicated, along with the background
VOIs (corresponding to the largest sphere volume; 26.5 mL). This representative
reconstruction of the phantom is of 223Ra acquired on the Discovery 670 with a
MEGP collimator.

At the low detected counts for αRPT, orders of
magnitude reduced from conventional SPECT tracer
studies (typically with 99mTc), the signal generated in
background following reconstruction is not
negligible. BV measures the variation of VOI means
over multiple VOIs. It takes into account the scatter
and the ensemble noise in the reconstructed image.
The BV was calculated with the following:
𝐵𝑉 =

�

1
∑𝐾 (𝑚𝑘 −𝑚
� )2
𝐾−1 𝑘=1

�
𝑚

(4);

where mk denotes the mean of pixels in kth
background VOI, 𝑚
� denotes the average of
background VOI means over different VOIs and K
denotes the number of background VOIs (K = 36).

Limits of detection
A laboratory-built phantom was created to
assess the limits of detection for each system,
configuration, and isotope. This phantom is
comprised of six 5 mL conical polypropylene vials
filled with a range of activity concentrations of each
radioisotope and four 5 mL conical polypropylene
vials filled with water arranged at the center (Figure
2). To cover the entire range of physiologically
relevant activities, two identical phantoms covering
alternate ranges of activity were evaluated. In the first
(high), vials contained 74, 37, 27.7, 18.5, 9.2, and 3.7
kBq/mL of each radioisotope and in the second (low),
the vials were filled with 20, 15, 5, 2, 1, and 0.5
kBq/mL. SPECT/CT acquisitions were acquired of
each limit of detection range, on each gamma camera
and with both collimators. The acquisition and
reconstruction parameters were identical to those
described above.

http://www.thno.org
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VOIs were defined as 10 ellipsoids surrounding
each vial, applied as above. The total number of
counts was obtained for each VOI and plotted in
function of the concentration of the radioisotope in the
vials. The limit of detection was achieved when the
number of counts in the VOI around the hot vial was
not above 10 times the number of counts in the
background. The background is determined as the
mean number of counts in the VOIs surrounding the
water filled vials.

Validation with anthropomorphic physical
phantoms
In order to validate the acquisition and
reconstruction protocol, a realistic tumor phantom
was imaged. In collaboration with the 3D Printing Lab
at Washington University, we modeled volumes
representative
of
a
realistic tumor
using
patient-data-derived tumor properties (size, shape)
and a vertebrae based on a patient CT image.
Computer-aided designs (CADs) were created in
Blender V 2.82. Molds and the lid of the phantom
were printed on Formlabs Form 2 3D printer with
elastic resin. Two fillable 3D phantoms were printed
(Figure 13 and Figure S12) [41]. The printed vertebrae
phantom was covered with a solution of Plaster of
Paris (calcium sulfate hemihydrate) to accurately
mimic bone attenuation. The volumes of the tumor
and vertebrae phantoms were 12 mL and 15 mL,
respectively. The choice of the tumor phantom
volume was based on patient-data-derived tumor
volume and on selecting a volume similar to one of
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the NEMA sphere for quantification purposes. The
vertebrae phantom was filled with 40 kBq/mL of
223Ra and the tumor phantom was filled with 35
kBq/mL of 225Ac and 227Th. For each configuration,
the phantom was fixed on the cylindrical insert inside
the NEMA phantom, which was filled with
non-radioactive water to recapitulate body scatter and
attenuation features.
A SPECT/CT acquisition on the Discovery 670
gamma camera with the MEGP collimator was
acquired for each phantom. The acquisition and
reconstruction parameters are the same as those
described above. A VOI was contoured on the CT and
applied on the SPECT data and counts inside both
tumor and vertebrae were determined. The activity in
the tumor was estimated using the calibration factor
as obtained from the experiments with the NEMA
phantom and compared to the true activity.

Results
Radioisotopes
Figure 3 (left panel) shows the high-resolution
gamma spectra of each source of the radioisotope
from measurements using the HPGe. The principal
photon emissions described in Table 1 are detected.
The characteristic gammas are 81.1, 83.8, 94.9, 154.2,
and 269.5keV for 223Ra; 218.2 and 440.5 keV for 225Ac,
and 236 keV for 227Th.

Energy spectrum

The energy spectrum for each isotope measured
on the Discovery 670 and the
Symbia T6 are shown in Figure 3
middle and left panel, respectively.
The characteristic photopeaks of
each isotope were measured and
defined by both gamma cameras.
For 223Ra, the 81.1 (15.0%), 83.8
(24.9%), and 94.9 keV (11.3%)
emissions were detected in a same
peak as were the 269.5 (13.7%) and
271.2 keV (10.8%) emissions because
of the limited gamma camera
energy resolution. The photons at
351.1 keV (12.9%) from 211Bi was
also visible in a photopeak at 350
keV. Moreover, the Symbia T6
measured both gammas at 401.8
(6.4%) and 404.9 keV (3.8%) in one
peak with the MELP collimator,
contrary to the Discovery 670,
which did not resolve this emission.
Figure 2. Limit of detection phantom scanned by the Optima 640 gamma-camera. The six identical conical
For 225Ac, two photopeaks
polypropylene vials are filled with different concentrations of 223Ra: 74, 37, 27.7, 18.5, 9.2, and 3.7 kBq/mL. The red
apart
from characteristic X-rays
circles denote the vials containing the hot sources while the green circles denote the vials filled with water.
(around 80 keV) coming from the
http://www.thno.org

Theranostics 2021, Vol. 11, Issue 20

9727

collimator were visible: the one at 218.2 keV (11.6%)
from 211Fr and at 440.5 keV (26.1%) from 213Bi. We
observed that while the characteristic 440 keV
emission of the 213Bi daughter of 225Ac was detected
appropriately at 440 keV on the Symbia T6, this
emission line was identified at 410 keV on the
Discovery 670. On both gamma cameras, we noted a
significant down scatter peak around 170 keV.
For 227Th, several peaks apart from the combined
peaks for characteristic X-rays (around 82 keV) were
visible. For example, the 236 keV (12.3%) gammas
from 227Th were detected. Moreover, the Symbia T6
gamma camera measured the 50.1 keV (8.0%) gammas

from 227Th, contrary to the Discovery 670 on which we
observed a decrease in signal, an aberration that may
be due to a specific energy channel issue with our
system. As the 227Th source was purified the day
before the measurement, the characteristic gammas of
223Ra were not discernable.
The emission and scatter energy windows
selected from the energy spectra measurements are
summarized in Table 4 and Table 5 for the GE and the
Symbia T6 Siemens SPECT/CT, respectively. Scatter
windows were not used for the Symbia T6 system, as
the system software does not allow the scatter
correction on multiple energy windows acquisition.

Figure 3. High resolution and clinical imaging system derived energy spectra of: A) 223Ra, B) 225Ac, C) 227Th. Left column: energy spectra measured by HPGe. Middle column:
energy spectra measured on the Discovery 670 (GE) with the MEGP and HEGP collimators. Right column: energy spectra measured on the Symbia T6 (Siemens) with the MELP
and HEGP collimators. The shaded areas are the chosen emission energy windows for SPECT evaluation.

Table 4. Emission and scatter energy windows chosen for each radioisotope on the Discovery 670 (GE)
Windows

223Ra

I
II
III

Emission windows
85 keV ± 20%
154 keV ± 20%
270 keV ± 10%

225Ac

Scatter windows
57 keV ± 17,5%
113 keV ± 8.8%
226.5 keV ± 7,2%

Emission windows
80 keV ± 20%
217.5 keV ± 8%
410 keV ± 6.1%

227Th

Scatter windows
57 keV ± 10.7%
165 keV ± 21.2%
365.5 keV ± 4.8%

Emission windows
50 keV ± 17.5%
82 keV ± 19%
239 keV ± 9%

Scatter windows
36 keV ± 13.8%
62.5 keV ± 5.6%
200 keV ± 5%

Table 5. Emission and scatter energy windows chosen for each radioisotope on the Symbia T6 (Siemens)
Windows
I
II
III

223Ra

85 keV ± 20%
154 keV ± 20%
270 keV ± 10%

225Ac
82 keV ± 20%
216.8 keV ± 8%
444.3 keV ± 5%

227Th

50.6 keV ± 20%
85.7 keV ± 15%
240 keV ± 9%
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Figure 4. Sensitivities measured on the three gamma cameras with both collimators, for the three isotopes: 223Ra (top), 225Ac (middle), 227Th (bottom). The energy windows I,
II and III are: 85 keV ± 20%, 154 keV ± 20%, and 270 keV ± 10% for 223Ra; 82 keV ± 20%, 216.8 keV ± 8%, and 444.3 keV ± 5% for 225Ac; 50.6 keV ± 20%, 85.7 keV ± 15%, and
240 keV ± 9% for 227Th.

Figure 5. SPECT/CT fusion of the NEMA phantom acquired on the Discovery 670 (GE) with the HEGP collimator. Images are of A) Spheres filled with 40 kBq/mL of 223Ra; B)
spheres filled with 35 kBq/mL of 225Ac, C) spheres filled with 40 kBq/mL of 227Th.

The sensitivities measured for 223Ra, 225Ac and
for each gamma camera configuration and each
emission window are presented in Figure 4. For each
isotope, the results obtained on the Symbia T6 with
the MELP collimator yielded the greatest computed
sensitivity. For each isotope, the sensitivity of the
HEGP collimator was lower than that determined
with the MEGP/MELP collimator. Measurement with
223Ra
achieved their highest sensitivity when
summing the three energy windows, which was
consistent across images using the MEGP/MELP
collimators for the three isotopes (Figure 3, left
column).
227Th

Quantitative phantom study
Figure 5 shows the reconstructed fused
SPECT/CT images of the NEMA phantom for the
three isotopes with the Discovery 670 SPECT/CT
equipped with the HEGP collimator. The emission
and scatter energy windows used for each isotope and
each gamma camera are summarized in Table 4 and
Table 5.
As expected from the sensitivity results (Figure
4), the resulting SPECT/CT images with 223Ra had the
greatest number of counts in the reconstructed
volumes. Except in the smallest sphere (20.8 kBq for
http://www.thno.org
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and 227Th and 18.2 kBq for 225Ac), all of the
spheres were visible. For brevity, representative
reconstructions for all additional data are presented in
the Supplemental Data.
For each reconstructed image and each sphere
dimension, the CF, SNR and BV were assessed.

Ra-223
As shown in Figure 8, on the Discovery 670 (GE),
the highest SNR with the MEGP and HEGP
collimators was obtained with the window I (85 keV ±
20%) and the window III (270 keV ± 10%),
respectively. Compared to the MEGP collimator, the
HEGP gave a higher calibration factor values: 2.5%
more for the largest sphere (3.7 cm diameter).
However, the BV was higher (1.3% for the largest
sphere-volume compared to the MEGP collimator)
and the SNR was lower. For instance, in the case of the
largest sphere, the SNR was 1.4% lower with the
HEGP collimator than with the MEGP collimator.
Analyzing imaging data from the Optima 640
(GE) showed that SNR for the window III was greater
with the HEGP collimator than with the MEGP
collimator (Figure S2). The MEGP collimator gave a
higher calibration factor and SNR; for example, with
the second largest sphere (2.8 cm diameter), they were
5.3% and 1.3% greater than with the HEGP collimator.
However, the BV was increased: 6.1% for the second
largest sphere compared to the HEGP collimator.
Similarly, using the Symbia T6 (Siemens), the
HEGP collimator yielded improved SNR for the
window III (Figure S3). Acquisitions with the MELP
collimator provided a higher calibration factor: 6.8%
greater for the largest sphere than with the HEGP
collimator. However, the BV was increased: 2.0% for
the largest sphere compared to the HEGP collimator.
The HEGP collimator gave increased SNR: 8.3%
higher for the largest sphere.
To summarize, for 223Ra acquisition parameters
and quantitative SPECT image metrics, the Symbia T6
with the HEGP collimator has given the highest
calibration factor and the lowest BV. However, except
for the largest sphere volume, the acquisitions using
the Discovery 670 with the HEGP collimator resulted
in greater SNR.

Ac-225
Using the Discovery 670 with the MEGP
collimator without scatter correction provided
improved imaging results (Figure S4) than with
correction, and these data are consistent with the
energy spectrum analysis. Indeed, the calibration
factor and SNR were 11.8% and 3.6% higher for the
largest sphere than with scatter correction. However,
the BV was 3.4% greater without scatter correction.
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The results were similar for the HEGP collimator
(Figure S5). The calibration factor, BV and SNR were
12.9%, 0.8% and 10.9% higher for the second largest
sphere compared to with scatter correction. To
summarize, the calibration factor for every sphere was
similar with both collimators (only 1.4% different with
the MEGP collimator for the largest sphere than with
the HEGP collimator, which was not significant) and a
lower BV. However, the SNR was higher with the
HEGP collimator: 8.8% for the largest sphere
compared to the MEGP collimator.
Similarly, using the Optima 640 with MEGP
collimation also demonstrated improved results
without scatter correction (Figure 7 and Figure S6).
The calibration factor and SNR were 13.3% and 3.6%
greater for the largest sphere than with scatter
correction. However, the BV increased by 2.6%. The
HEGP collimator also provided better results without
scatter correction (Figure 9). The calibration factor and
SNR were 14.6% and 12.6% greater for the second
largest sphere than with scatter correction. However,
the BV was 3.0% greater. In summary, the HEGP
collimator offered a similar calibration factor (1.1% for
the largest sphere compared to MEGP, which was not
significant) and increased SNR (5.6% for the largest
sphere). Moreover, the BV was higher with the MEGP
collimator: 10.6% for the largest sphere.
On the Symbia T6, the HEGP collimator offered a
better calibration factor and SNR: 3.7% and 5.6% for
the largest sphere (Figure S7). However, the BV was
higher with the HEGP collimator: 6.6% for the largest
sphere.
Overall, the Symbia T6 with the HEGP
collimator gave the highest calibration factor and SNR
across the systems tested for 225Ac. For example, in the
case of the largest sphere, it was 49.7% and 9.5% more
than the Discovery 670 and 49.7% and 2.5% higher
than the Optima 640. However, the BV was also
increased for the largest sphere obtained with the
Symbia T6: 5.7% compared to the Discovery 670 and
6.7% to the Optima 640.

Th-227
Acquisitions using the Discovery 670 showed
that the window I (50 keV ± 17.5%) and the window
III (239 keV ± 9%) had similar calibration factors with
the MEGP collimator (Figure S8). The window II (82
keV ± 19%) offered the highest calibration factor and
the 239 keV emission window the highest SNR. The
results were slightly better without scatter correction.
Indeed, the calibration factor and SNR were 3.2% and
1.1% higher than with scatter correction for the largest
sphere. These observations were the same for the
HEGP collimator (Figure S9). The calibration factor
and SNR were 3.0% and 0.8% higher than with scatter
http://www.thno.org
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correction for the largest sphere. Consequently, the
MEGP collimator offered a better calibration factor
and SNR: 2.5% and 7.6% for the second largest sphere
compared to the HEGP collimator. Moreover, the BV
was higher with the HEGP collimator: 1.0% for the
second largest sphere.
On the Optima 640 system, the calibration
factors, SNR and BV were also similar for the MEGP
and HEGP collimators. For both collimators, the
windows I and III (50 keV and 239 keV) had similar
calibration factors. The second emission window (82
keV) offered the highest calibration factor, which was
consistent with the sensitivity results (Figure S10 and
Figure S11). With the MEGP collimator, the
calibration factor was higher without scatter
correction: 2.9% for the second largest sphere.
However, the SNR was higher and the BV was lower
with scatter correction: 2.2% and 2.1% for the second
largest sphere. With the HEGP collimator, the
calibration factor and SNR were higher without
scatter correction: 3.3% and 0.6% for the largest
sphere. As a result, the HEGP collimator gave a higher
calibration factor: 3.0% for the second largest sphere.
However, the SNR was higher and the BV was lower
with the MEGP collimator: 5.5% and 5.5% for the
second largest sphere.
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On the Symbia T6, the MELP collimator offered a
better calibration factor and SNR: 12.6% and 9.4% for
the second largest sphere. However, the BV was
higher: 3.2% for the second largest sphere (Figure 6
and Figure 10).
To summarize, the Symbia T6 with the MEGP
collimator gave the highest calibration factor and
SNR: 49.5% and 10.7% compared to the Discovery 670
and 49.5% and 9.4% compared to the Optima 640 for
the largest sphere. Moreover, the BV was less
important in the images obtained with the Symbia T6:
6.9% compared to the Discovery 670 and 4.8%
compared to the Optima 640 for the largest sphere.
Figure 11 recapitulates the calibration factor,
SNR and BV measured for the three isotopes on the
optimally determined configuration for each system.

Limit of detection
Figure 12 shows an example of the SPECT/CT
acquisition of the detection limit measurements. For
the high activity phantom, all of the sample activities
were visible except the lowest activity concentration
(3.7 kBq/mL) (Figure 12A-C). Using the phantom
with a lower activity concentration range; only the
three higher activity concentrations were detectable
above background: 20, 15, and 5 kBq/mL (Figure
12B-C).

Figure 6. SPECT/CT fusion of the NEMA phantom acquired on the Symbia T6 (Siemens) with the MELP collimator. The phantom was filled with 40 kBq/mL of 227Th. A)
Reconstructed image of the 50.6 keV ± 20% emission window, B) reconstructed image of the 85.7 keV ± 15% emission window, C) reconstructed image of the 240 keV ± 9%
emission window.

Figure 7. SPECT/CT fusion of the NEMA phantom acquired on the Optima 640 (GE) with the MEGP collimator. The phantom spheres were filled with 35 kBq/mL of 225Ac. A)
Reconstructed image of the 217.5 keV ± 8% emission window without scatter correction, B) Reconstructed image of the 217.5 keV ± 8% emission window with scatter
correction.
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Figure 8. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 223Ra for each energy window and combination of the energy
windows. Representative data acquired on the Discovery 670 (GE) with the MEGP (left column) and HEGP (right column) collimators.

The detection limits phantoms filled with 223Ra
were imaged with the Discovery 670 (GE)
and
equipped with a HEGP collimator and the MEGP
collimator, respectively. The detection-limit phantoms
filled with 225Ac were imaged with the Symbia T6
(Siemens) equipped with a HEGP collimator. The
limit of detectability was determined as 5 kBq/mL for
every isotope, and the linearity of response was also
assessed (Figure 12D).
227Th

Validation with anthropomorphic physical
phantoms
In order to evaluate tomographic image quality
in a controlled real-world scenario, we evaluated
anthropomorphic 3D-printed structures. Figure 13
and Figure S12 show SPECT/CT acquisitions of the
vertebrae and tumor phantoms (described in
Methods) filled with 223Ra, 225Ac, and 227Th. Table 6
summarizes quantification of these images obtained
by using the calibration factor measured on the
NEMA phantom for the largest sphere [36]. The
results show the possibility to quantifying the activity
of 223Ra and 225Ac with an error lower than 4%. In the
case of 227Th, quantification was still possible but with
a substantially larger error.

Table 6. Summary of quantification results with the 3 isotopes
measured on calibrated SPECT/CT images acquired on the
Discovery 670 with the MEGP collimator
Isotope
223Ra
225Ac
227Th

Real activity (MBq)
0.597
0.401
0.404

Measured activity (MBq)
0.609
0.386
0.356

Error (%)
2.1
3.5
11.8

Discussion
This study investigates the capabilities to acquire
and quantify SPECT of three ⍺-emitting radioisotopes:
223Ra, 225Ac, and 227Th at activity levels commensurate
with RPT applications on clinically relevant imaging
systems. Three state-of-the-art gamma cameras that
are widely deployed for conventional diagnostic
nuclear medicine applications were evaluated: the
Discovery 670 and Optima 640 from GE and the
Symbia T6 from Siemens, and energy windows and
collimator settings were tested for their impact on
image quantitation.
Of the α-emitting agents used in imaging
studies, parameters for 223Ra and 225Ac with planar
imaging have been the most widely reported [13-15,
18, 19, 21, 22, 28, 42]. Quantitative SPECT
http://www.thno.org

Theranostics 2021, Vol. 11, Issue 20
investigations are much less common, involving both
223Ra [23-25] and 225Ac [43-46]. Most recently, a case
report has demonstrated the feasibility of dosimetry
on a patient with a PSMA-targeted 225Ac agent [30].
The authors used HEGP collimation and two (218 keV
and 440 keV) energy windows, but quantification of
activity concentration was not reported. To date, no
peer reviewed study of 227Th SPECT/CT has been
published, despite the active interest in this area [47]
and the potential of scintigraphy for 227Th
quantification [48].
To comprehensively evaluate ⍺-emitter SPECT,
an optimized acquisition protocol was first
determined for each isotope. To that end, an energy
spectrum was acquired on both the GE Discovery 670
and the Siemens Symbia T6 in order to determine
appropriate energy windows. Diverging from the
most commonly used tracers (Technetium-99m and
Indium-111), the reconstruction protocol was
optimized by acquiring SPECT/CT of the NEMA
phantom. We used vendor-recommended reconstruction parameters, including the number of
iterations and subsets and post-reconstruction filters.
These reconstruction parameters varied between
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systems. The role of scatter correction in activity
estimation was investigated, along with limits of
detection, for each isotope and each system. Finally,
the acquisition and reconstruction protocol were
validated
using
anthropomorphic
3D-printed
phantoms.
Our data establish that three-energy emission
windows are recommended in order to provide
higher count statistics and improve the image quality.
While SNR can degrade with a multiwindow
approach, the improved sensitivity is important
towards the eventual goal of quantification of patient
tissue activity concentrations. Scatter correction using
the DEW technique is not recommended for 225Ac and
227Th as it decreases sensitivity. However, scatter
correction has the intended effect of decreasing noise
in reconstructions. Since these ⍺-emitters have low
detectable photons, we suggest that sensitivity is an
important study design criterion. More recently,
methods that been proposed which use the
scatter-window data for the quantification task [49],
which may achieve the goals of both improving
sensitivity and accomplishing scatter correction.

Figure 9. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 225Ac for each energy window and combination of energy windows.
The images were acquired on the Optima 640 (GE) with the HEGP collimator with scatter correction (left column) and without (right column).
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Figure 10. Calibration factors, SNR and BV measured on SPECT/CT images of the NEMA phantom filled with 227Th for each energy window and combination of energy windows.
The representative data were acquired on the Symbia T6 (Siemens) with the MELP (left column) and HEGP (right column) collimators.

Figure 11. Comparison of the calibration factors, SNR and BV between gamma cameras for the three isotopes. Left: Radium. The NEMA phantom was acquired with the HEGP
collimator for the Discovery 670 and the Symbia T6 and with the MEGP collimator for the Optima 640. Center: Actinium. The NEMA phantom was acquired with the HEGP
collimator for the Optima 640 and the Symbia T6 and with the MEGP collimator for the Discovery 670. Right: Thorium. The NEMA phantom was imaged with the MEGP/MELP
collimator for the three gamma-camera.

http://www.thno.org

Theranostics 2021, Vol. 11, Issue 20

9734

Figure 12. Transaxial and coronal slice from the SPECT/CT fusion of the Limit of Detection phantom acquired on the Discovery 670 (GE) with the MEGP collimator for 227Th.
A) Limit of detection phantom with higher activities scale of 227Th. B) SPECT of lower scale limit of detection phantom. C) Gradient of activities per sample arranged in order of
activity concentration (high: 74, 37, 27.7, 18.5, 9.2 and 3.7 kBq/mL, and low: 20, 15, 5, 2, 1 and 0.5 kBq/mL). D) Plot of the number of reconstructed counts detected in the hot
tubes as a function of concentration.

being detected compared to the MEGP
collimator owing to the thicker and taller
septum. The thicker septa help reduce the
septal penetration by higher energy
photons. This explains why the SNR
measured in the higher energy window
with the HEGP collimator is greater the
MEGP, for each isotope.
At our center, for the imaging of 223Ra,
we recommend using the Discovery 670
with the HEGP collimator. The HEGP and
Symbia T6 is recommended for imaging
225Ac. Finally, the Symbia T6 with the
MEGP collimator is suggested for imaging
227Th. These configurations are derived
from a compromise between sensitivity
and noise characteristics, illustrated in
Figure 13. 3D-printed Vertebrae phantom. A) Picture of a 3D printed Vertebrae. B) CAD of the
Vertebrae showing the fillable space. C) The Vertebrae phantom was fixed on the cylindrical insert inside
Figure 11. Overall, our findings also
the NEMA phantom SPECT/CT images of the 3D-printed vertebrae phantom acquired on the Discovery
demonstrate that the Symbia T6 is more
670 with the MEGP collimator. Transaxial and Sagittal views of the Vertebrae phantom filled with 40
kBq/mL of 223Ra. Top: CT view. Middle: NM view. Bottom: NM/CT fusion.
sensitive under the test conditions. This
result might be explained by the larger
crystal dimensions, as well as differences
The NEMA phantom studies allow one to adapt
in
signal
processing
electronics. The calibration factor
the calibration factor for different lesion sizes [39]. The
measured
on
the
Symbia
T6 is 50% higher than the
calibration factor determined from our acquisitions
one
assessed
on
both
GE
cameras
for each sphere and
decreases with decreasing sphere volume. For smaller
isotope evaluated.
spheres, the visual contrast and calibration factor
We have observed that under our experimental
decreased due to partial volume effects. The
SPECT conditions, system configuration and image
3D-printed
tissue
phantoms
showed
that
quality with 223Ra was greater than for 225Ac and 227Th.
quantification is achievable with the three
This is likely due to the fact that the gamma emission
alpha-emitters on the three different systems.
abundance for 223Ra exceeds that of the other isotopes
The choice of the collimator is a tradeoff between
and its photopeaks coincide with a range (100-300
the sensitivity of the measurement and the observed
keV) for which detector efficiency is highest. In
signal to noise ratio. The characteristics of both
addition, higher energy gamma rays, as observed
collimators used for each system were summarized in
with 225Ac, cause performance degrading effects such
Table 3; briefly, the MEGP collimator has smaller hole
as increasing septal penetration and down-scatter that
diameter and thinner and shorter septa. The HEGP
complicate reconstruction and quantification tasks.
collimator prevents more unscattered photons from
http://www.thno.org
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Our measurements under the various
experimental conditions in this work have import for
interpretation and design of clinical SPECT/CT
efforts. In clinical practice, patients receive 55 kBq/kg
of 223Ra every 4 weeks for 6 cycles. Pharmacokinetic
studies have shown that the principal organ at risk is
the bone marrow [7, 17]. In Pacilio et al. [22] and
Murray et al. [15], the authors reported an average
total lesion size of 87 mL (1.2 to 270 mL in 14 patients
and 53 lesions) for osteoblastic bone metastasis of
prostate cancer. However, in the context of osteolytic
bone metastasis of kidney cancer, the target of new
clinical trials [50], lesions are much smaller (average
volume of 0.6 mL specifically, 0.1-5.1 mL in 10
patients and 66 lesions) [51]. Therefore, taking into
consideration a limit of detection of 5 kBq/mL, the
lowest detectable activity in an averaged sizes
osteoblastic lesion would represent approximately
10% of the injected activity for an 80 kg patient. In the
case of an osteolytic lesion, it would represent about
0.07% of the injected activity for the same patient.
Thus, we predict that our protocol will enable the
quantification of osteoblastic bone metastasis (with a
significant uptake) whereas, for osteolytic bone
metastasis, partial volume correction will be
necessary to obtain a more robust quantification.
A range of peptide and antibody 225Acformulated agents are under clinical trial evaluation.
225Ac-PSMA-617 is perhaps the most well described
[26-28]. Consequently, lesions dimensions are similar
as described above for 223Ra. Our study shows that the
quantification of 225Ac SPECT images is achievable.
Recently, Gosewisch et al. demonstrates feasibility of
quantitative SPECT imaging in a patient injected with
225Ac-PSMA [30]. The authors used two energy
windows centered on the 218 and 440 keV
photopeaks. They were able to perform a dosimetry
study on the patient kidneys and a small lesion. Renal
clearance of low molecular weight radiopharmaceuticals makes the kidney an organ of
considerable interest for these efforts. The use of a
specific phantom such as a 3D-printed kidney
phantom [52] may be necessary to properly calibrate a
gamma camera for the specific task of quantitative
alpha particle emitting agent SPECT. Indeed, studies
have shown that spill-out effects become more
relevant in organs whose shapes differ significantly
from a spherical geometry and that sphere-based
calibration factor lookup tables should be replaced by
a more geometry-specific alternative [53, 54].
Moreover, VOI delineation for nonuniform structures
is a significant contributor to uncertainty in RPT
dosimetry [55], and it is important to optimize the
calibration for ill-defined objects. Similarly, SPECT
methods that quantify uptake directly from the

9735
projection data show promise for improved
quantification even with non-spherical structures
evaluated for 223Ra [56], and this approach may be
expanded to include other emitters.
Phase I clinical trials using 227Th conjugates
targeting lymphoma, mesothelioma and prostate
cancer are ongoing (NCT02581878, NCT03507452,
NCT03724747). For 227Th-labeled anti-PSMA agents,
as for 223Ra and 225Ac-labeled PSMA-inhibitors, our
protocol demonstrates the feasibility of quantifying
lesion uptake. Previous work by Hammer et al. [57]
has identified the organs at risk as the liver and
spleen. Similar to 225Ac, the use of organ specific
phantoms may be necessary for accurate calibration of
the gamma cameras.
The initial daughter of 227Th is 223Ra, which may
have an independent biodistribution to that of the
parent conjugate. Quantitative in vivo imaging with
conventional systems is challenging due to cross-talk
between neighboring gammas as well as scattered
gamma photons. This might explain a greater
difference in the quantification results from our
realistic phantoms studies. In the present study, all
the 227Th acquisitions have been performed within 24
h after purification, and further study may be
required to evaluate quantification at later timepoints
from in-growth of daughter emitters. Larsson et al.
[48] and Murray et al. [34] have proposed a
methodology using different energy windows for
planar imaging in this context. Li et al. [56] proposed a
multiple-energy-window projection-domain quantification method that jointly estimates the regional
activity uptake of both 227Th and 223Ra directly using
the SPECT projection data from multiple energy
windows.
This
method
yielded
accurate
quantification and further work to validate planar and
SPECT efforts are ongoing.
A primary focus in this work was hardware
configuration evaluation of multiple isotopes,
however software considerations in the clinical setting
are also important. The acquisition protocol for each
isotope has been determined and optimized on each
systems’ software, using settings recommended by
the vendor. Nevertheless, the reconstruction and
post-reconstruction settings used in this study could
be further optimized for quantification. Indeed,
precise reconstruction methods have to take into
account the scatter and attenuation of each isotope
emission in the system matrix of the iterative
reconstruction algorithms. In our experience, clinical
software workflows may not at this time be well
suited for multiple photon emissions. Thus, more
advanced methods, such as those based on Monte
Carlo simulations, may help improve the accuracy of
SPECT/CT reconstruction and thus quantify uptake
http://www.thno.org
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more accurately.

Conclusion
SPECT/CT imaging is, and will continue to be,
an important tool in the development of new
therapeutic radiopharmaceuticals, as it provides a
means to assess the biodistribution in patients
following administration. However, great care has to
be taking for system calibration and acquisition
protocol development and implementation. The
present work demonstrates quantification of 223Ra,
225Ac, and 227Th activity on SPECT/CT images is
feasible on standard double-headed SPECT/CT
which are widely deployed in the field. Further,
configurations have been elaborated that will enable
accurate detection and quantitation of activity
concentrations from α-emitters in clinical use. The
methodology developed in this study will be useful
for the other α emitting isotope of clinical interest
such as 212Pb or 211At.
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